Yousif Capital Management LLC Sells 2,576 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Yousif Capital Management LLC cut its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,218 shares of the pharmaceutical company's stock after selling 2,576 shares during the period. Yousif Capital Management LLC's holdings in Vertex Pharmaceuticals were worth $12,702,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in VRTX. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $25,000. Arlington Trust Co LLC raised its holdings in shares of Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 33 shares during the period. Fortitude Family Office LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $30,000. Baystate Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company's stock valued at $31,000 after purchasing an additional 25 shares during the period. Finally, NBC Securities Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $34,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the company's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company's stock, valued at approximately $23,755,762.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the company's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares of the company's stock, valued at approximately $31,819,732.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ourania Tatsis sold 354 shares of the company's stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company's stock, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock worth $5,203,249 in the last quarter. Insiders own 0.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VRTX. Guggenheim upped their target price on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a "buy" rating in a report on Thursday, April 18th. HC Wainwright increased their price target on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a "buy" rating in a report on Thursday, April 11th. Robert W. Baird cut shares of Vertex Pharmaceuticals from a "neutral" rating to an "underperform" rating and set a $325.00 price target on the stock. in a report on Wednesday, January 31st. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Finally, Canaccord Genuity Group reissued a "sell" rating and issued a $371.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $429.45.

Vertex Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ VRTX traded down $4.15 during trading on Wednesday, hitting $400.76. 805,906 shares of the company traded hands, compared to its average volume of 1,240,464. The business's fifty day moving average is $412.66 and its 200 day moving average is $398.38. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $316.43 and a fifty-two week high of $448.40. The firm has a market capitalization of $103.58 billion, a price-to-earnings ratio of 28.85, a P/E/G ratio of 1.88 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts' consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the business posted $3.33 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.